Next Article in Journal
Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases
Previous Article in Journal
Hemoglobin Reassembly of Antimicrobial Fragments from the Midgut of Triatoma infestans
Previous Article in Special Issue
Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting
Open AccessReview

Recent Advances in Allogeneic CAR-T Cells

Department of Biochemistry, BK21 PLUS Program for Creative Veterinary Science Research and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(2), 263; https://doi.org/10.3390/biom10020263
Received: 16 January 2020 / Revised: 7 February 2020 / Accepted: 7 February 2020 / Published: 10 February 2020
(This article belongs to the Special Issue Advances in Antibody Therapy of Cancer)
In recent decades, great advances have been made in the field of tumor treatment. Especially, cell-based therapy targeting tumor associated antigen (TAA) has developed tremendously. T cells were engineered to have the ability to attack tumor cells by generating CAR constructs consisting of genes encoding scFv, a co-stimulatory domain (CD28 or TNFRSF9), and CD247 signaling domains for T cell proliferation and activation. Principally, CAR-T cells are activated by recognizing TAA by scFv on the T cell surface, and then signaling domains inside cells connected by scFv are subsequently activated to induce downstream signaling pathways involving T cell proliferation, activation, and production of cytokines. Many efforts have been made to increase the efficacy and persistence and also to decrease T cell exhaustion. Overall, allogeneic and universal CAR-T generation has attracted much attention because of their wide and prompt usage for patients. In this review, we summarized the current techniques for generation of allogeneic and universal CAR-T cells along with their disadvantages and limitations that still need to be overcome.
Keywords: CAR-T; switch molecule; universal CAR-T; allogeneic; cancer CAR-T; switch molecule; universal CAR-T; allogeneic; cancer
MDPI and ACS Style

Kim, D.W.; Cho, J.-Y. Recent Advances in Allogeneic CAR-T Cells. Biomolecules 2020, 10, 263.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop